<div id="readability-page-1"><div><p>Danish pharmaceutical company Genmab has finalized its offer for all outstanding common shares in Merus. With this acquisition, the drug candidate petosemtamab, which holds two Breakthrough Therapy Designations, is now part of Genmab's portfolio.</p><p>  Genmab anticipates that petosemtamab will have a positive impact on EBITDA, projecting an annual sales potential of at least $1 billion through 2029, and subsequently, an annual revenue potential in the multi-billion dollar range.</p><p>  &#34;We are energized by the potential of petosemtamab to make a difference for patients with head and neck cancer,&#34; said CEO Jan van de Winkel in a press release.</p><p>Genmab now controls a total of 94.2 percent of Merus and has decided to give shareholders another opportunity to accept the offer by extending the acceptance period by ten trading days, until December 29. The offered price remains at $97 per share.</p></div></div>

MRUS

GMAB

<p>Genmab has completed its acquisition of Merus, adding the cancer treatment petosemtamab to its portfolio. Petosemtamab, with two Breakthrough Therapy Designations, is expected to positively impact EBITDA and generate annual sales of at least $1 billion by 2029. Genmab now controls 94.2% of Merus and has extended the offer acceptance period until December 29, maintaining the price at $97 per share.</p>

Genmab Completes Acquisition of Merus – Bolsters Portfolio with New Cancer Treatment